BioSpace News Archive

MaxCyte, a leading provider of platform technologies for cell engineering, announced the appointment of Rekha Hemrajani and Yasir Al-Wakeel, BM BCh, to the company’s board of directors as non-executive directors with immediate effect.

Taysha Gene Therapies, Inc.today announced its participation in virtual fireside chats at the LifeSci Genetics Medicine Conference and LSX Biotech Growth CEO Forum.

Lexaria Bioscience Corp. is pleased to announce positive results from its tolerability and pharmacokinetic animal study VIRAL-A20-2, evaluating DehydraTECH-enabled remdesivir and ebastine.

CRISPR Therapeutics and Capsida Biotherapeutics Inc .today announced a strategic partnership to research, develop, manufacture and commercialize in vivo gene editing therapies delivered with engineered AAV vectors for the treatment of familial amyotrophic lateral sclerosis (ALS) and Friedreich’s ataxia.

Sutro Biopharma, Inc. today announced that Chief Executive Officer, Bill Newell , will participate in two virtual investor conferences in June.

Newly created roles will support StrideBio’s operations across strategy, regulatory affairs, quality, and patient advocacy.

Salarius Pharmaceuticals, Inc. today announced the initiation of a clinical trial to investigate seclidemstat, a novel lysine specific demethylase 1 (LSD1) inhibitor, as a potential treatment for hematologic cancers.

Otonomy, Inc. today announced the initiation of an expansion study for the Phase 1/2 clinical trial of OTO-413 in patients with speech-in-noise hearing difficulty.

PharmaTher Holdings Ltd. is pleased to announce that it has filed a pre-Investigational New Drug meeting request and complete pre-IND briefing package with the U.S. FDA to support the clinical development of KETABET™ and the proposed Phase 2 clinical study as a potential next-generation treatment for depression, and to discuss the product development plan for the Company’s patented hydrogel-forming microneedle patch delivery technology.

Oryzon Genomics, S.A. announced today that it has received confirmation from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug application (IND) for vafidemstat is now open to conduct a Phase IIb clinical trial in patients with Borderline Personality Disorder (BPD).